CD38 as a Regulator of Cellular NAD: A Novel Potential Pharmacological Target for Metabolic Conditions

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|15|1|57-63

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.15, Iss.1, 2009-01, pp. : 57-63

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

CD26 / Dipeptidyl Peptidase IV: A Regulator of Immune Function and a Potential Molecular Target for Therapy

By  

Current Drug Targets - Immune, Endocrine & Metabolic Disorders, Vol. 4, Iss. 1, 2004-03 ,pp. : 11-18

Bentham Science Publishers

Access to resources Recommend Favorite

NAD(P)H Oxidase Activation: A Potential Target Mechanism for Diabetic Vascular Complications, Progressive &bgr;-Cell Dysfunction and Metabolic Syndrome

By  

Current Drug Targets, Vol. 6, Iss. 4, 2005-06 ,pp. : 495-501

Bentham Science Publishers

Access to resources Recommend Favorite

NAD Metabolism and Functions: A Common Therapeutic Target for Neoplastic, Metabolic and Neurodegenerative Diseases

By  

Current Topics in Medicinal Chemistry, Vol. 13, Iss. 23, 2013-12 ,pp. : 2918-2929

Bentham Science Publishers

Access to resources Recommend Favorite

CD26: A Multi-Purpose Pharmacological Target

By  

Current Clinical Pharmacology, Vol. 9, Iss. 2, 2014-05 ,pp. : 157-164

Bentham Science Publishers

Access to resources Recommend Favorite

p38 MAPK: A Potential Target of Chronic Pain

By  

Current Medicinal Chemistry, Vol. 21, Iss. 38, 2014-01 ,pp. : 4405-4418

Bentham Science Publishers

Access to resources Recommend Favorite